Genfit S A Quick Ratio (GNFT) starting from the fourth quarter 2024 to fourth quarter 2023, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Genfit S a   (NASDAQ: GNFT)

Genfit S A 's Quick Ratio

GNFT's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the fourth quarter 2024, Quick Ratio fell to 0.82 below Genfit S A average.

Within Biotechnology & Pharmaceuticals industry 129 other companies have achieved higher Quick Ratio than Genfit S A in fourth quarter 2024. While Quick Ratio total ranking in the fourth quarter 2024 has deteriorated compared to the prior quarter from 881 to 1765.

Explain Quick Ratio?
How much Cash & cash equivalents GNFT´s has?
What are GNFT´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/GNFT/financial-strength
https://api.csimarket.com/api/v1/companies/GNFT/fundamentals
https://api.csimarket.com/api/v1/companies/GNFT/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
GNFT Quick Ratio (Dec 31 2024)
Q4		 0
Q3 		0
Q2 		0
Q1 		(Dec 31 2023)
Q4
Y / Y Current Liabilities Change 61.54 %
Y / Y Cash & cash equivalent Change -1.62 %
Quick Ratio MRQ 0.82
GNFT's Total Ranking # 1765
Seq. Current Liabilities Change 22.6 %
Seq. Cash & cash equivalent Change -7.58 %



Quick Ratio fourth quarter 2024 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 130
Healthcare Sector # 669
Overall Market # 1765


Quick Ratio Statistics
High Average Low
6.34 3.75 1.09
(Dec 31 2019)   (Dec 31 2024)




Financial Statements
Genfit S A 's Current Liabilities $ 103 Millions Visit GNFT's Balance sheet
Genfit S A 's Cash & cash equivalent $ 85 Millions Visit GNFT's Balance sheet
Source of GNFT's Sales Visit GNFT's Sales by Geography


Cumulative Genfit S A 's Quick Ratio

GNFT's Quick Ratio for the trailling 12 Months

GNFT Quick Ratio

 (Dec 31 2024)
12 Months		 0
12 Months 		0
12 Months 		0
12 Months 		(Dec 31 2023)
12 Months
Y / Y Current Liabilities TTM Growth 84.15 %
Y / Y Cash & cash equivalent TTM Growth 3.47 %
Quick Ratio TTM 1.01
Total Ranking TTM # 4031
Seq. Current Liabilities TTM Growth 12.43 %
Seq. Cash & cash equivalent TTM Growth -0.39 %

Quick ratio ranking by company, industry and sector >> Back to GNFT Financial Strength Comparisons >> Go to Compare GNFT Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q4 2024 to $103.21 millions, cumulative Quick Ratio decreased to 1.01 below the Genfit S A average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 160 other companies have achieved higher Quick Ratio than Genfit S A . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2024 from 3839 to 4031.

Explain Quick Ratio?
How much Cash & cash equivalents GNFT´s has?
What are GNFT´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 161
Healthcare Sector # 996
Within the Market # 4031


trailing twelve months Quick Ratio Statistics
High Average Low
6.34 3.73 1.09
(Dec 31 2019)   (Dec 31 2024)




Companies with similar Quick Ratio in the quarter ending Dec 31 2024, within Biotechnology & Pharmaceuticals Industry Quick RatioDec 31 2024 MRQ Cash & cash equivalentDec 31 2024 MRQ Current Liabilities
Humacyte Inc   2.25 $ 44.937  Millions$ 19.954  Millions
Cognition Therapeutics inc   2.24 $ 25.009  Millions$ 11.142  Millions
Monte Rosa Therapeutics Inc   2.12 $ 372.149  Millions$ 175.731  Millions
Cardiol Therapeutics inc   2.08 $ 21.236  Millions$ 10.214  Millions
Biomx Inc  2.04 $ 16.856  Millions$ 8.267  Millions
Biocryst Pharmaceuticals Inc   2.00 $ 321.060  Millions$ 160.384  Millions
Lenz Therapeutics Inc   1.94 $ 20.158  Millions$ 10.406  Millions
Adma Biologics Inc   1.90 $ 103.147  Millions$ 54.181  Millions
Meiragtx Holdings Plc  1.71 $ 103.659  Millions$ 60.783  Millions
Immunitybio inc   1.69 $ 149.809  Millions$ 88.799  Millions
Beam Therapeutics Inc   1.55 $ 281.967  Millions$ 182.066  Millions
Neurocrine Biosciences Inc   1.54 $ 1,076.100  Millions$ 697.500  Millions
Intensity Therapeutics Inc   1.51 $ 2.600  Millions$ 1.727  Millions
Dbv Technologies S a   1.47 $ 32.456  Millions$ 22.154  Millions
Century Therapeutics inc   1.46 $ 189.292  Millions$ 129.782  Millions
Tradeup Acquisition Corp  1.40 $ 4.165  Millions$ 2.973  Millions
Qiagen N v   1.32 $ 982.059  Millions$ 746.227  Millions
Innate Pharma Sa  1.28 $ 68.726  Millions$ 53.491  Millions
C4 Therapeutics Inc   1.23 $ 55.499  Millions$ 45.177  Millions
Invivyd Inc   1.14 $ 69.349  Millions$ 60.672  Millions
Argenx Se  1.14 $ 1,499.936  Millions$ 1,319.909  Millions
Curis Inc   1.13 $ 19.997  Millions$ 17.691  Millions
Bio techne Corp  1.10 $ 177.549  Millions$ 161.256  Millions
Biocardia Inc   1.02 $ 2.371  Millions$ 2.321  Millions
Calidi Biotherapeutics Inc   1.01 $ 9.591  Millions$ 9.496  Millions
Sangamo Therapeutics Inc   0.92 $ 41.918  Millions$ 45.805  Millions
Cellectis S a   0.86 $ 143.251  Millions$ 166.269  Millions
Halozyme Therapeutics Inc   0.83 $ 115.850  Millions$ 139.100  Millions
Genfit S a   0.82 $ 84.659  Millions$ 103.210  Millions
Novavax inc   0.80 $ 923.118  Millions$ 1,154.416  Millions

Date modified: 2026-09-18T13:11:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.